Ruby Qc Investment Holdings Pte Ltd, a Singapore-based investment entity, has completed the disposal of its entire shareholding in Akums Drugs & Pharma through a block deal transaction. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on December 22, 2025.

Transaction Details

The disposal involved the complete divestment of Ruby Qc Investment Holdings' stake in the pharmaceutical company. The transaction details are presented below:

Shareholding Pattern Changes

The disposal represents a complete exit by Ruby Qc Investment Holdings from Akums Drugs & Pharma. The shareholding pattern changes are detailed below:

Regulatory Compliance

The disclosure was filed with both the National Stock Exchange of India Limited and BSE Limited, where Akums Drugs & Pharma shares are listed. Ruby Qc Investment Holdings Pte Ltd, incorporated in Singapore with registration number 201905580M, completed all regulatory requirements under SEBI's substantial acquisition regulations.

Company Information

Ruby Qc Investment Holdings Pte Ltd is registered at 55 Paterson Road, Singapore 238550, with Abrar Mir serving as Director. The entity has been operating as an investment holding company incorporated in the Republic of Singapore.

The transaction marks the complete exit of the Singapore-based investment entity from the Indian pharmaceutical company, with no remaining shareholding or encumbrances following the December 22, 2025 block deal execution.

Akums Drugs & Pharma has informed stock exchanges about an additional penalty imposed on its wholly-owned subsidiary Maxcure Nutravedics Limited by Gujarat tax authorities. The disclosure follows a previous announcement regarding regulatory action by the same authorities.

Penalty Details

The Office of the Deputy Commissioner of State Tax, Gujarat, has imposed an additional penalty of ₹1.80 crore under Section 129(3) of the CGST Act, 2017. This penalty is in addition to the amount already disclosed, bringing the cumulative financial impact to significant levels.

Nature of Violation

The penalty stems from shipping address errors in invoices and e-way bills. According to the company's disclosure, the shipping address was mistakenly entered incorrectly in the invoice and e-way bill documentation, leading to the regulatory action by Gujarat State Tax authorities.

Financial Impact Assessment

The company has provided a comprehensive assessment of the total financial impact from both penalties. The cumulative effect includes the current penalty along with the previously disclosed amount.

Regulatory Compliance

Akums Drugs & Pharma has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information as required under the SEBI Master Circular, including the nature of violation, authority details, and financial impact assessment.

Company Response

The disclosure indicates that while the total penalty amount of ₹3.59 crore represents a significant sum, the company has assessed it as not material to its overall financial, operational, or other activities. This assessment suggests the penalty amount is manageable within the company's current financial framework and operational scale.